Literature DB >> 18662814

Decreased Mrp2-dependent bile flow in the post-warm ischemic rat liver.

Daisuke Ban1, Atsushi Kudo, Shaoguang Sui, Shinji Tanaka, Noriaki Nakamura, Koji Ito, Makoto Suematsu, Shigeki Arii.   

Abstract

BACKGROUND: The link between microcirculatory disturbance and hepatocellular dysfunction remains unknown. The present study was designed to examine the key event of warm ischemia reperfusion (WIR) injury with subsequent cholestasis.
METHODS: A left lobar 70% ischemia and reperfusion rat model was used in this study. The portal vein and hepatic artery to the left lateral lobe of the liver were subjected to 20 min of warm ischemia followed by 60 min of reperfusion to collect bile and to measure its constituents.
RESULTS: The hepatocellular injury was increased significantly in livers exposed to WIR, as judged by serum alanine aminotransferase. This event coincided with decreased bile production and biliary concentration of glutathione (GSH), suggesting impaired bile salts-independent bile flow, while biliary phospholipids and bile salts were not decreased. Additionally, hepatic adenosine triphosphate and GSH were not decreased after WIR. Since the biliary GSH, which is a major driving force for bile salts-independent bile flow, is excreted from hepatocytes into the bile via multidrug resistance protein 2 (Mrp2), we examined whether intracellular localization of Mrp2 occurred. Immunohistochemical analyses revealed hepatocellular Mrp2 was retrieved from bile canalicular membrane into the pericanalicular cytoplasm in the post-warm ischemic livers. Microcirculatory disturbance in livers exposed to 20 min of warm ischemia improved to levels comparable to controls.
CONCLUSION: Mrp2 internalization, observed in this study, may play an important determinant of cholestasis in the post-warm ischemic livers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18662814     DOI: 10.1016/j.jss.2008.02.064

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

1.  Mitochondrial metabolism in the noncancerous liver determine the occurrence of hepatocellular carcinoma: a prospective study.

Authors:  Atsushi Kudo; Kaoru Mogushi; Tadatoshi Takayama; Satoshi Matsumura; Daisuke Ban; Takumi Irie; Takanori Ochiai; Noriaki Nakamura; Hiroshi Tanaka; Naohiko Anzai; Michiie Sakamoto; Shinji Tanaka; Shigeki Arii
Journal:  J Gastroenterol       Date:  2013-03-30       Impact factor: 7.527

2.  Anticholestatic Effect of Bardoxolone Methyl on Hepatic Ischemia-reperfusion Injury in Rats.

Authors:  Joohyun Kim; Catherine E Hagen; Suresh N Kumar; Jong-In Park; Michael A Zimmerman; Johnny C Hong
Journal:  Transplant Direct       Date:  2020-07-17

3.  Effects of hepatic ischemia-reperfusion injury on the P-glycoprotein activity at the liver canalicular membrane and blood-brain barrier determined by in vivo administration of rhodamine 123 in rats.

Authors:  Mohammad K Miah; Imam H Shaik; Ulrich Bickel; Reza Mehvar
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

4.  Gd-EOB-DTPA-enhanced MRI for quantitative assessment of liver organ damage after partial hepatic ischaemia reperfusion injury: correlation with histology and serum biomarkers of liver cell injury.

Authors:  Tobias Getzin; Faikah Gueler; Björn Hartleben; Marcel Gutberlet; Anja Thorenz; Rongjun Chen; Martin Meier; Jan Hinrich Bräsen; Thorsten Derlin; Dagmar Hartung; Hannah A S Lang; Hermann Haller; Frank Wacker; Song Rong; Katja Hueper
Journal:  Eur Radiol       Date:  2018-04-30       Impact factor: 5.315

5.  Impact of recombinant globular adiponectin on early warm ischemia-reperfusion injury in rat bile duct after liver transplantation.

Authors:  Yang Xia; Jian-Ping Gong
Journal:  Sci Rep       Date:  2014-09-19       Impact factor: 4.379

6.  Protective effect of gadolinium chloride on early warm ischemia/reperfusion injury in rat bile duct during liver transplantation.

Authors:  Biao Wang; Qi Zhang; Bili Zhu; Zhonglin Cui; Jie Zhou
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.